Cellectis S.A. (CLLS)
Cellectis develops cell therapies for cancer and genetic diseases using gene editing, and licenses its technology to drug developers. It last closed at $0.92 on Nov 20, down 6.39% on the day.
Key Stats
Fiscal 2025Not reported for this period.
From CLLS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 20). Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on CLLS
Technical AnalysisPrices may be delayed
The stock is 20% below its 20 day and 34% below its 50 day average. It is 210% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38), near oversold. The nearest support is the 52 week low at $0.88, and the nearest resistance the Pivot at $0.94.
| RSI (14) | 37.74 | Weak, oversold below 30 | Neutral |
| MACD | -0.08 | Below its signal line | Bearish |
| Stochastic | 4.8 | Near the bottom of its range | Oversold |
| ADX (14) | 26.3 | Trending down | |
| Williams %R | -97.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -134.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −13.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.13 | Typical daily range, 14.7% of price |
| RSI (14) | 28.06 | Oversold below 30 | Oversold |
| MACD | -0.63 | Below its signal line | Bearish |
| Stochastic | 6.5 | Near the bottom of its range | Oversold |
| ADX (14) | 28.4 | Trending down | |
| Williams %R | -98.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -86.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −70.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.43 | Typical daily range, 46.2% of price |
What happened before
See how CLLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CLLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
Whale Options FlowPrices may be delayed
90DNo whale options trades in CLLS in the last 90 days.
CLLS Institutional Ownership
Full report →- ▲12 buying vs 9 selling
- ●Shares held by funds +0.3%
- ▲Funds holding +4
- ●No superinvestor moves
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 31 | 27 | +14.8% |
| In funds' top 10 | 0 | 1 | −100.0% |
| Held by funds | – | – | – |
| New / increased | 8 / 4 | 3 / 1 | +200.0% |
| Reduced / sold out | 4 / 5 | 8 / 8 | −43.8% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLLS is in one of them and how their past CLLS trades turned out.
CLLS News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CLLS in an article yet. Here's the latest on the wider market.
- Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
- Part I – Financial Information
- Cellectis to Report Third Quarter Financial Results on November 12, 2026
- Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
About Cellectis S.A.
Cellectis is a biotechnology company based in Paris, France, that develops cell and gene therapies using gene editing. Its main focus is cancer treatments made from CAR T cells taken from healthy donors, which can be produced in batches and shipped as ready to use products rather than made for each patient. The company also develops gene therapies for genetic diseases and licenses its technology to drug developers such as AstraZeneca, Allogene, Servier and Iovance.
- Headquarters
- Paris, Lle-De-France
- Founded
- 1999
- Website
- cellectis.com ↗